Matthew Keller
Stock Analyst at HC Wainwright & Co.
(n/a)
# 5,015
Out of 5,182 analysts
12
Total ratings
9.09%
Success rate
-26.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Keller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHIO Phio Pharmaceuticals | Reiterates: Buy | $14 | $1.21 | +1,057.02% | 2 | Feb 10, 2026 | |
| SXTP 60 Degrees Pharmaceuticals | Maintains: Buy | $6 → $24 | $1.62 | +1,381.48% | 2 | Jan 27, 2026 | |
| IFRX InflaRx | Reiterates: Buy | $6 | $1.61 | +272.67% | 2 | Dec 30, 2025 | |
| GALT Galectin Therapeutics | Maintains: Buy | $6 → $11 | $2.37 | +364.14% | 2 | Dec 17, 2025 | |
| SNSE Sensei Biotherapeutics | Downgrades: Neutral | n/a | $31.54 | - | 1 | Oct 30, 2025 | |
| ACXP Acurx Pharmaceuticals | Reiterates: Buy | $31 | $2.03 | +1,427.09% | 2 | Sep 30, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $18 | $7.65 | +135.29% | 1 | Aug 26, 2025 |
Phio Pharmaceuticals
Feb 10, 2026
Reiterates: Buy
Price Target: $14
Current: $1.21
Upside: +1,057.02%
60 Degrees Pharmaceuticals
Jan 27, 2026
Maintains: Buy
Price Target: $6 → $24
Current: $1.62
Upside: +1,381.48%
InflaRx
Dec 30, 2025
Reiterates: Buy
Price Target: $6
Current: $1.61
Upside: +272.67%
Galectin Therapeutics
Dec 17, 2025
Maintains: Buy
Price Target: $6 → $11
Current: $2.37
Upside: +364.14%
Sensei Biotherapeutics
Oct 30, 2025
Downgrades: Neutral
Price Target: n/a
Current: $31.54
Upside: -
Acurx Pharmaceuticals
Sep 30, 2025
Reiterates: Buy
Price Target: $31
Current: $2.03
Upside: +1,427.09%
Gyre Therapeutics
Aug 26, 2025
Initiates: Buy
Price Target: $18
Current: $7.65
Upside: +135.29%